Clin2
NCT06772428Likely a fitNot yet recruiting

Megestrol acetate for head and neck cancer after surgery

Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors

Treatments studied

Part of Cancer, Ear, nose & throat clinical trials.

This trial tests whether a special form of megestrol acetate can help prevent cancer from coming back in people with high-risk head and neck cancer who have had surgery. It is for patients who need additional treatment with radiation or chemoradiation after their operation.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
96 people
Ages
18 years to 85 years
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have been diagnosed with squamous cell carcinoma of the head and neck (mouth, throat, voice box, or lower throat).
  • You had surgery for this cancer within the last 6 weeks.
  • Your doctor says you have high-risk features and need radiation with or without chemotherapy after surgery.
  • You are able to eat and digest food normally (no tube feeding or IV nutrition).
  • You do not have AIDS, severe nausea/vomiting, or a mental health condition causing loss of appetite.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07150663Recruiting· Phase 3
Megestrol acetate with chemoradiation for stage III lung cancer

This study tests whether a special form of megestrol acetate (a medicine used to help with weight and appetite) can improve outcomes when given alongside standard chemotherapy and radiation for people with stage III non-small cell lung cancer. It is for patients who are not overweight and who are not already using other appetite-boosting medications.

Wuhan, Hubei
NCT07130617Not yet recruiting· Phase 1
Megestrol acetate for nausea and vomiting from strong chemo

This trial tests a medicine called megestrol acetate to see if it can prevent nausea and vomiting caused by very strong chemotherapy for lung cancer. If you are starting a strong chemo treatment, this study may help you feel better.

Guangzhou, Guangdong
NCT07338487Recruiting· Phase 1
Nanocrystalline megestrol acetate with chemoradiation for advanced cervical cancer

This trial tests a newer form of megestrol acetate (a medication that can help with appetite and weight) given alongside standard chemotherapy and radiation for locally advanced cervical cancer that cannot be removed by surgery. The study aims to see if this combination is safe and effective.

Changsha, Hunan
NCT06830018Recruiting
New megestrol for advanced stomach or colon cancer with fatigue

This study tests a new form of megestrol (a medicine that can boost appetite and energy) for people with advanced stomach or colorectal cancer who also have fatigue and poor appetite. It is given as a first treatment, meaning you haven't had chemotherapy yet for your advanced cancer.

Shenyang, Liaoning
NCT07477808Not yet recruiting· Phase 3
Megestrol acetate for advanced lung cancer with weight loss

This trial tests whether a medicine called megestrol acetate can help improve appetite and weight in people with advanced lung cancer who are malnourished. It's for those who haven't had chemotherapy for their advanced cancer yet.

NCT06998758Recruiting· Phase 3
Megestrol Acetate for weight loss during chemo in advanced colorectal cancer

This trial tests if taking megestrol acetate (a medicine used to stimulate appetite and help gain weight) can reduce weight loss caused by chemotherapy in people with locally advanced colorectal cancer. It may help you maintain strength and energy during treatment.

Guangzhou, Guangdong

Hear when a new Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.